SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates

Exclusion Criteria

• •1. Known pregnant and/or lactating women.
• •2. Participant with a known significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study
• •3. Active haematological malignancy diagnosis
• •4. Known or suspected scalp metastases at screening
• •5. Planned concurrent alopecia-inducing therapy during ADC treatment (e.g. whole-brain radiotherapy or cytotoxic chemotherapy)
• •6. History of cold intolerance syndromes (e.g. cryoglobulinaemia, cold agglutinin disease, or cold urticaria)
• •7. Active scalp dermatological disease likely to interfere with cooling or assessments (e.g. lupus erythematosus, lichen planus)
• •8. Known hypersensitivity to device cap materials or coolant
• •9. Uncontrolled migraine or chronic headache disorders worsened by cold exposure, in the investigator's judgement
• •10. Participants who have already started treatment with an ADC prior to randomisation will be excluded, as scalp cooling must begin with the first ADC infusion